

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

JHOS-4

RRID:CVCL_4649

Type: Cell Line

Proper Citation

RRID:CVCL_4649

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4649

Proper Citation: RRID:CVCL_4649

Description: Cell line JHOS-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:22460905](#), [PMID:23839242](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: JHOS-4

Synonyms: JHOS4

Cross References: CLO:CLO_0051443, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:903, BioSample:SAMN03472117, BioSample:SAMN10987614, cancercellines:CVCL_4649, Cell_Model_Passport:SIDM00303, Cosmic-CLP:1480359, DepMap:ACH-000584, EGA:EGAS00001000978, GDSC:1480359, GEO:GSM887179, GEO:GSM888251, GEO:GSM1669957, IARC_TP53:28380, LiGeA:CCLE_693, PharmacDB:JHOS4_691_2019, PRIDE:PXD003668, PRIDE:PXD030304,

Progenetix:CVCL_4649, RCB:RCB1678, Wikidata:Q54898659

ID: CVCL_4649

Record Creation Time: 20220427T220646+0000

Record Last Update: 20260905T180905+0000

Ratings and Alerts

No rating or validation information has been found for JHOS-4.

No alerts have been found for JHOS-4.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kimura N, et al. (2026) CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. Cancer research communications, 6(2), 383.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. Advanced biology, 10(3), e00404.

Wang K, et al. (2025) Molecular mechanisms of CAND2 in regulating SCF ubiquitin ligases. Nature communications, 16(1), 1998.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience, 27(7), 109978.

Tsuchimochi S, et al. (2023) Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma. Scientific reports, 13(1), 20292.